Desensitization and down-regulation of neurotensin receptors in murine neuroblastoma clone N1E-115 by [D-Lys8] neurotensin(8- 13)

E. D. Di Paola, B. Cusack, M. Yamada, E. Richelson

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Clone N1E-115 cells have specific, high-affinity binding sites for neurotensin (NT). These receptors mediate formation of cyclic GMP and other second messengers. We studied the effects of extended exposure of cells to [D-Lys8]NT(8-13) (NT2), a peptidase-resistant NT analog, on NT's ability to stimulate cyclic GMP synthesis and to bind [3H]NT to its sites on these cells. When intact N1E-115 cells were preincubated with NT2 (1 μM) for various times (15 min to 12 hr) at 37°C, maximal desensitization and binding site (B(max)) loss occurred after only 15 min. Receptor affinity for [3H]NT did not change. At 0°C NT2 for 15 min caused no down-regulation. After 15 min of preincubation with NT2 at 37°C, the recovery of receptor binding and function after a 10 to 20 min lag-time was rapid (T( 1/2 ) = 15 min and 19 min, for binding and cyclic GMP response, respectively). After 12 hr of NT2 preincubation, it was slow (T( 1/2 ) = 212 min). Incubation of cells with cycloheximide (70 μM) for 5 hr after their exposure to NT2 for 15 min did not change the rate or extent of recovery of NT B(max). However, cycloheximide did decrease the recovery of NT B(max) after exposure of cells to NT2 for 12 hr. Cycloheximide alone did not change NT B(max). These data suggest that this decrease of NT receptor binding after short (15 min) and long (12 hr) exposure times to agonist involves two consecutive steps: intracellular sequestration of recyclable NT receptors, followed by receptor degradation causing true down-regulation.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalJournal of Pharmacology and Experimental Therapeutics
Volume264
Issue number1
StatePublished - 1993

Fingerprint

neurotensin (8-13)
Neurotensin Receptors
Neurotensin
Neuroblastoma
Down-Regulation
Clone Cells
Cyclic GMP
Cycloheximide
Binding Sites
Second Messenger Systems
Peptide Hydrolases

ASJC Scopus subject areas

  • Pharmacology

Cite this

Desensitization and down-regulation of neurotensin receptors in murine neuroblastoma clone N1E-115 by [D-Lys8] neurotensin(8- 13). / Di Paola, E. D.; Cusack, B.; Yamada, M.; Richelson, E.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 264, No. 1, 1993, p. 1-5.

Research output: Contribution to journalArticle

@article{c38a88332d5c42a287adda4f3cfbb5a5,
title = "Desensitization and down-regulation of neurotensin receptors in murine neuroblastoma clone N1E-115 by [D-Lys8] neurotensin(8- 13)",
abstract = "Clone N1E-115 cells have specific, high-affinity binding sites for neurotensin (NT). These receptors mediate formation of cyclic GMP and other second messengers. We studied the effects of extended exposure of cells to [D-Lys8]NT(8-13) (NT2), a peptidase-resistant NT analog, on NT's ability to stimulate cyclic GMP synthesis and to bind [3H]NT to its sites on these cells. When intact N1E-115 cells were preincubated with NT2 (1 μM) for various times (15 min to 12 hr) at 37°C, maximal desensitization and binding site (B(max)) loss occurred after only 15 min. Receptor affinity for [3H]NT did not change. At 0°C NT2 for 15 min caused no down-regulation. After 15 min of preincubation with NT2 at 37°C, the recovery of receptor binding and function after a 10 to 20 min lag-time was rapid (T( 1/2 ) = 15 min and 19 min, for binding and cyclic GMP response, respectively). After 12 hr of NT2 preincubation, it was slow (T( 1/2 ) = 212 min). Incubation of cells with cycloheximide (70 μM) for 5 hr after their exposure to NT2 for 15 min did not change the rate or extent of recovery of NT B(max). However, cycloheximide did decrease the recovery of NT B(max) after exposure of cells to NT2 for 12 hr. Cycloheximide alone did not change NT B(max). These data suggest that this decrease of NT receptor binding after short (15 min) and long (12 hr) exposure times to agonist involves two consecutive steps: intracellular sequestration of recyclable NT receptors, followed by receptor degradation causing true down-regulation.",
author = "{Di Paola}, {E. D.} and B. Cusack and M. Yamada and E. Richelson",
year = "1993",
language = "English (US)",
volume = "264",
pages = "1--5",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Desensitization and down-regulation of neurotensin receptors in murine neuroblastoma clone N1E-115 by [D-Lys8] neurotensin(8- 13)

AU - Di Paola, E. D.

AU - Cusack, B.

AU - Yamada, M.

AU - Richelson, E.

PY - 1993

Y1 - 1993

N2 - Clone N1E-115 cells have specific, high-affinity binding sites for neurotensin (NT). These receptors mediate formation of cyclic GMP and other second messengers. We studied the effects of extended exposure of cells to [D-Lys8]NT(8-13) (NT2), a peptidase-resistant NT analog, on NT's ability to stimulate cyclic GMP synthesis and to bind [3H]NT to its sites on these cells. When intact N1E-115 cells were preincubated with NT2 (1 μM) for various times (15 min to 12 hr) at 37°C, maximal desensitization and binding site (B(max)) loss occurred after only 15 min. Receptor affinity for [3H]NT did not change. At 0°C NT2 for 15 min caused no down-regulation. After 15 min of preincubation with NT2 at 37°C, the recovery of receptor binding and function after a 10 to 20 min lag-time was rapid (T( 1/2 ) = 15 min and 19 min, for binding and cyclic GMP response, respectively). After 12 hr of NT2 preincubation, it was slow (T( 1/2 ) = 212 min). Incubation of cells with cycloheximide (70 μM) for 5 hr after their exposure to NT2 for 15 min did not change the rate or extent of recovery of NT B(max). However, cycloheximide did decrease the recovery of NT B(max) after exposure of cells to NT2 for 12 hr. Cycloheximide alone did not change NT B(max). These data suggest that this decrease of NT receptor binding after short (15 min) and long (12 hr) exposure times to agonist involves two consecutive steps: intracellular sequestration of recyclable NT receptors, followed by receptor degradation causing true down-regulation.

AB - Clone N1E-115 cells have specific, high-affinity binding sites for neurotensin (NT). These receptors mediate formation of cyclic GMP and other second messengers. We studied the effects of extended exposure of cells to [D-Lys8]NT(8-13) (NT2), a peptidase-resistant NT analog, on NT's ability to stimulate cyclic GMP synthesis and to bind [3H]NT to its sites on these cells. When intact N1E-115 cells were preincubated with NT2 (1 μM) for various times (15 min to 12 hr) at 37°C, maximal desensitization and binding site (B(max)) loss occurred after only 15 min. Receptor affinity for [3H]NT did not change. At 0°C NT2 for 15 min caused no down-regulation. After 15 min of preincubation with NT2 at 37°C, the recovery of receptor binding and function after a 10 to 20 min lag-time was rapid (T( 1/2 ) = 15 min and 19 min, for binding and cyclic GMP response, respectively). After 12 hr of NT2 preincubation, it was slow (T( 1/2 ) = 212 min). Incubation of cells with cycloheximide (70 μM) for 5 hr after their exposure to NT2 for 15 min did not change the rate or extent of recovery of NT B(max). However, cycloheximide did decrease the recovery of NT B(max) after exposure of cells to NT2 for 12 hr. Cycloheximide alone did not change NT B(max). These data suggest that this decrease of NT receptor binding after short (15 min) and long (12 hr) exposure times to agonist involves two consecutive steps: intracellular sequestration of recyclable NT receptors, followed by receptor degradation causing true down-regulation.

UR - http://www.scopus.com/inward/record.url?scp=0027369149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027369149&partnerID=8YFLogxK

M3 - Article

VL - 264

SP - 1

EP - 5

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -